Stocks
Summit Therapeutics Sets November 14 FDA PDUFA Date for Ivonescimab
Summit Therapeutics has received a November 14 PDUFA date for its ivonescimab BLA. The company is also planning the HARMONi-3 PFS trial...
#biotechnology 14 articles
Stocks
HHS, VA Memorandum Boosts Psychedelic Drugmakers
A new memorandum of understanding between HHS and the VA could significantly benefit companies developing psychedelic-based drug treatments for veterans.
Stocks
Definium Therapeutics Prices $700M Public Offering
Definium Therapeutics announced the pricing of an upsized public offering, raising approximately $700 million in gross proceeds.
Stocks
Biogen Acquires RayThera for Up to $1 Billion, Bolstering Immunology Pipeline
Biogen Inc. announced an agreement to acquire private biotech RayThera Inc. for up to $1 billion, significantly expanding its immunology portfolio with...
Stocks
Incyte’s Monjuvi Lifts Lymphoma Survival 25% in Late-Stage Trial
Incyte's immunotherapy Monjuvi, developed with Xencor, demonstrated a 25% improvement in cancer-free survival in a late-stage trial for a common lymphoma type,...
Stocks
NervGen Pharma Prices $60 Million Public Offering
NervGen Pharma Corp. has priced a public offering of common shares and warrants, raising $60 million to advance its neuroreparative therapeutics.
Stocks
Ars Pharmaceuticals Expands $199 Access Program, Awaits CVS Caremark Decision
Ars Pharmaceuticals is expanding its $199 neffy retail access program while awaiting a crucial decision from CVS Caremark, aiming to boost affordability...
Stocks
LENZ Therapeutics Reports Q1 2026 Performance, Targets 15,000 HCPs
LENZ Therapeutics delivered Q1 2026 results consistent with expectations, achieving $1.9 million in net revenue and approximately 25,000 prescriptions. The company also...
Stocks
Vaxart Sets Early 2027 Efficacy Readout, Q2 Sentinel Data Release Imminent
Vaxart (VXRT) anticipates a primary efficacy readout for its oral vaccine platform in early 2027, with a Q2 sentinel data release expected...